Alyeska Investment Group L.P. boosted its stake in TESARO Inc (NASDAQ:TSRO) by 37.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 407,505 shares of the biopharmaceutical company’s stock after acquiring an additional 110,820 shares during the quarter. Alyeska Investment Group L.P. owned 0.75% of TESARO worth $52,609,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Exane Derivatives acquired a new stake in TESARO in the 3rd quarter valued at $106,000. Botty Investors LLC acquired a new stake in TESARO in the 2nd quarter valued at $140,000. Nordea Investment Management AB acquired a new stake in TESARO during the 2nd quarter worth $167,000. Oppenheimer Asset Management Inc. boosted its stake in TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank boosted its stake in TESARO by 244.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares during the last quarter.

Several equities research analysts have issued reports on the stock. Credit Suisse Group set a $190.00 target price on shares of TESARO and gave the stock a “buy” rating in a research note on Friday, August 18th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 target price on shares of TESARO in a research note on Monday, November 20th. Evercore ISI assumed coverage on shares of TESARO in a research note on Wednesday, August 16th. They set an “in-line” rating and a $121.00 target price on the stock. SunTrust Banks reaffirmed a “buy” rating and set a $160.00 target price on shares of TESARO in a research note on Friday, November 10th. Finally, Argus set a $154.00 target price on shares of TESARO and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. TESARO has an average rating of “Buy” and a consensus target price of $159.39.

In other news, SVP Martin H. Jr. Huber sold 592 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director James O. Armitage sold 10,000 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,421 shares of company stock worth $1,312,175. Corporate insiders own 40.50% of the company’s stock.

TESARO Inc (NASDAQ:TSRO) opened at $84.39 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. TESARO Inc has a 1 year low of $79.03 and a 1 year high of $192.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company’s revenue was up 740.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.72) EPS. sell-side analysts expect that TESARO Inc will post -8.17 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/12/09/tesaro-inc-tsro-shares-bought-by-alyeska-investment-group-l-p.html.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.